Jefferies Upgrades Corbus Pharmaceuticals to Buy, Raises Price Target to $46
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft upgraded Corbus Pharmaceuticals (NASDAQ:CRBP) from Hold to Buy and increased the price target from $4 to $46, indicating a positive outlook on the company's future performance.
March 06, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jefferies upgraded Corbus Pharmaceuticals to Buy and raised the price target significantly from $4 to $46, showing strong confidence in the company's prospects.
The upgrade from Hold to Buy by a reputable analyst, along with a substantial increase in the price target, suggests a strong positive sentiment towards Corbus Pharmaceuticals. This is likely to influence investor perception positively in the short term, potentially leading to an increase in stock price as market participants adjust their positions based on this new information.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100